The global Hepatitis Drugs Market is projected to witness CAGRof 3.2% throughout the forecast period (2019 – 2027), owing toincreasing number of regulatory approvals of hepatitis drugs. Forexample, in 2017 Gilead Sciences, Inc. announced that the EuropeanCommission had granted marketing authorization for Vemlidy (tenofoviralafenamide) for the treatment of chronic hepatitis B virus (HBV)infection in adults and adolescents (aged 12 years and older).
The HepatitisDrugs Market size is expected to witness remarkable growth onthe forecast period owing to increasing prevalence of hepatitis. Forexample, according to the World Health Organization (WHO), in 2017,around 71 million people were infected by chronic hepatitis Cworldwide. Furthermore, WHO considers Middle East and Europe to beprobably the most affected regions with the prevalence rate of 2.3%and 1.5% respectively. Moreover, in 2016, according to the Centersfor Disease Control and Prevention, around 2.7 to 3.9 million peoplein the U.S. have problems with hepatitis C.
Besides, the Hepatitis Drugs Market is expected to foresee the launchof generic versions of existing brands. For example, in 2018 GileadSciences launched generic versions of Harvoni and Epclusa, productsapproved for the treatment of Hepatitis C.
Read More@https://bit.ly/2RWht1r
